表紙
市場調查報告書

轉甲狀腺蛋白類澱粉沉積症 (ATTR):市場考察,流行病學,市場預測 ∼2027年

Familial Amyloid Polyneuropathy - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 524411
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
轉甲狀腺蛋白類澱粉沉積症 (ATTR):市場考察,流行病學,市場預測 ∼2027年 Familial Amyloid Polyneuropathy - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

(7MM:美國·法國·德國·義大利·西班牙·英國·日本) 的轉甲狀腺蛋白類澱粉沉積症 (ATTR)的主要7個國家市場規模,2016年時刻達到著6450萬美元。

(7MM) 的轉甲狀腺蛋白類澱粉沉積症 (ATTR)的市場相關分析本報告提供全球主要7個國家,疾病概要和背景情況,目前診斷·治療方法,各國的流行病學的情形 (患病人數的轉變),治療藥臨床實驗趨勢與今後的預測,主要的治療藥的簡介,全球整體及各國的市場規模 (治療藥銷售額)的趨勢預測等調查評估。

第1章 主要考察

第2章 轉甲狀腺蛋白類澱粉沉積症 (ATTR) 市場概要

  • ATTR市場:佔有率結構 (2016年)
  • ATTR市場:佔有率結構 (2017年)

第3章 疾病的背景情況和概要:轉甲狀腺蛋白類澱粉沉積症 (ATTR)

  • 簡介
  • ATTR的臨床性方面
  • ATTR的種類
  • 疾病的原因
  • ATTR的症狀
  • 發病狀態
  • ATTR的診斷方法
    • hATTR (toransusairechin型遺傳性) 類澱粉蛋白沉積症與症狀重複的疾病
    • hATTR類澱粉蛋白沉積症關聯了的危險的前兆
    • hATTR類澱粉蛋白沉積症診斷的確認
    • TTR-FAP (toransusairechin型家族性類澱粉沉積神經病變)的進展的評估工具
    • 腕隧道症候群的檢測工具

第4章 流行病學和患者人口

  • 分析的要點
  • 患者人口與預測變數
  • (7MM)的ATTR主要7個國家的受診完畢患病人數
  • (7MM)的ATTR主要7個國家的受診完畢患病人數:各類型

第5章 各國的流行病學的情形:轉甲狀腺蛋白類澱粉沉積症 (ATTR)

  • 美國
    • ATTR的受診完畢患病人數
    • ATTR的受診完畢患病人數:各類型
    • ATTR的治療可能的病例數
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 ATTR相關的腕隧道症候群的受診完畢手術數量

  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 目前治療·診療慣行

  • 治療流程
  • ATTR心類澱粉蛋白沉積症的支持的·非疾病修正治療
  • 治療指南
    • TTR-FAP的診斷·管理·治療相關,第一個歐洲共識 (European Consensus)
  • toransusairechin (TTR)的分期:症狀的重症度別
  • TTR-FAP的治療流程

第8章 未滿足需求

第9章 已上市治療藥

  • Vyndaqel (Pfizer Inc.)
    • 藥物的說明
    • 作用機制
    • 法規的里程碑
    • 優點·缺點
    • 安全性·功效
    • 現在進行中的臨床實驗的概要
    • 產品簡介

第10章 新治療方法

第11章 國際市場上的競爭趨勢

第12章 第三階段·登記完畢的治療藥

  • Patisiran (Alnylam Pharmaceuticals)
  • Inotersen (Ionis Pharmaceuticals Inc.)
    • 藥物的說明
    • 產品簡介
    • 法規的里程碑
    • 其他開發活動
    • 臨床開發
    • 臨床實驗資訊
    • 安全性·功效

第13章 第二階段的治療藥

  • CRX-1008 (Corino Therapeutics Inc.)

第14章 轉甲狀腺蛋白類澱粉沉積症 (ATTR):市場分析

第15章 主要分析結果

  • 在 (7MM) 的ATTR:主要7個國家市場分析
  • 在ATTR:主要7個國家的治療藥為基礎的市場規模
  • 在ATTR:主要7個國家的治療藥為基礎的市場規模:各類型
  • 家族性類澱粉沉積神經病變 (FAP)
  • 遺傳性Amyloid心肌病 (FAC)
  • 非遺傳性TTR/WT-TTR (野生型TTR)

第16章 轉甲狀腺蛋白類澱粉沉積症 (ATTR)的市場規模:各國明細

  • 美國市場
    • ATTR的市場規模:各類型
    • ATTR的市場規模:治療藥為基礎的
    • ATTR的市場規模:治療藥為基礎的,各類型
  • (EU5)的市場分析歐洲5個國家
  • 德國市場
  • 法國市場
  • 西班牙市場
  • 義大利市場
  • 英國市場
  • 日本市場

第17章 推動市場要素

第18章 阻礙市場要素

第19章 附錄

  • 分析方法

第20章 DelveInsight的服務內容

第21章 免責聲明

第22章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0082

DelveInsight's "Familial Amyloid Polyneuropathy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Familial Amyloid Polyneuropathy, historical and forecasted epidemiology as well as the Familial Amyloid Polyneuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Familial Amyloid Polyneuropathy market report provides current treatment practices, emerging drugs, Familial Amyloid Polyneuropathy market share of the individual therapies, current and forecasted Familial Amyloid Polyneuropathy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Familial Amyloid Polyneuropathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Familial Amyloid Polyneuropathy Disease Understanding and Treatment Algorithm

The DelveInsight Familial Amyloid Polyneuropathy market report gives a thorough understanding of the Familial Amyloid Polyneuropathy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Familial Amyloid Polyneuropathy.

Treatment

It covers the details of conventional and current medical therapies available in the Familial Amyloid Polyneuropathy market for the treatment of the condition. It also provides Familial Amyloid Polyneuropathy treatment algorithms and guidelines in the United States, Europe, and Japan.

Familial Amyloid Polyneuropathy Epidemiology

The Familial Amyloid Polyneuropathy epidemiology division provide insights about historical and current Familial Amyloid Polyneuropathy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Familial Amyloid Polyneuropathy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Familial Amyloid Polyneuropathy Epidemiology

The epidemiology segment also provides the Familial Amyloid Polyneuropathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Familial Amyloid Polyneuropathy Drug Chapters

Drug chapter segment of the Familial Amyloid Polyneuropathy report encloses the detailed analysis of Familial Amyloid Polyneuropathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Familial Amyloid Polyneuropathy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Familial Amyloid Polyneuropathy treatment.

Familial Amyloid Polyneuropathy Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Familial Amyloid Polyneuropathy treatment.

Familial Amyloid Polyneuropathy Market Outlook

The Familial Amyloid Polyneuropathy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Familial Amyloid Polyneuropathy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Familial Amyloid Polyneuropathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Familial Amyloid Polyneuropathy market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Familial Amyloid Polyneuropathy market in 7MM.

The United States Market Outlook

This section provides the total Familial Amyloid Polyneuropathy market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Familial Amyloid Polyneuropathy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Familial Amyloid Polyneuropathy market size and market size by therapies in Japan is also mentioned.

Familial Amyloid Polyneuropathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Familial Amyloid Polyneuropathy market or expected to get launched in the market during the study period 2017-2030. The analysis covers Familial Amyloid Polyneuropathy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Familial Amyloid Polyneuropathy Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Familial Amyloid Polyneuropathy key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Familial Amyloid Polyneuropathy emerging therapies.

Reimbursement Scenario in Familial Amyloid Polyneuropathy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Familial Amyloid Polyneuropathy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Familial Amyloid Polyneuropathy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Familial Amyloid Polyneuropathy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Familial Amyloid Polyneuropathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Familial Amyloid Polyneuropathy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Familial Amyloid Polyneuropathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Familial Amyloid Polyneuropathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Familial Amyloid Polyneuropathy market

Report Highlights

  • In the coming years, Familial Amyloid Polyneuropathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Familial Amyloid Polyneuropathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Familial Amyloid Polyneuropathy. Launch of emerging therapies will significantly impact the Familial Amyloid Polyneuropathy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Familial Amyloid Polyneuropathy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Familial Amyloid Polyneuropathy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Familial Amyloid Polyneuropathy Pipeline Analysis
  • Familial Amyloid Polyneuropathy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Familial Amyloid Polyneuropathy Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Familial Amyloid Polyneuropathy Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Familial Amyloid Polyneuropathy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Familial Amyloid Polyneuropathy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Familial Amyloid Polyneuropathy total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Familial Amyloid Polyneuropathy market size during the forecast period (2017-2030)?
  • At what CAGR, the Familial Amyloid Polyneuropathy market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Familial Amyloid Polyneuropathy market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Familial Amyloid Polyneuropathy market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Familial Amyloid Polyneuropathy?
  • What is the historical Familial Amyloid Polyneuropathy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Familial Amyloid Polyneuropathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Amyloid Polyneuropathy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Familial Amyloid Polyneuropathy during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Familial Amyloid Polyneuropathy treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Familial Amyloid Polyneuropathy in the USA, Europe, and Japan?
  • What are the Familial Amyloid Polyneuropathy marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Familial Amyloid Polyneuropathy?
  • How many therapies are developed by each company for Familial Amyloid Polyneuropathy treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Familial Amyloid Polyneuropathy treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Familial Amyloid Polyneuropathy therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Familial Amyloid Polyneuropathy and their status?
  • What are the key designations that have been granted for the emerging therapies for Familial Amyloid Polyneuropathy?
  • What are the global historical and forecasted market of Familial Amyloid Polyneuropathy?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Familial Amyloid Polyneuropathy market
  • To understand the future market competition in the Familial Amyloid Polyneuropathy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Amyloid Polyneuropathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Amyloid Polyneuropathy market
  • To understand the future market competition in the Familial Amyloid Polyneuropathy market

Table of Contents

1. Key Insights

2. Executive Summary of Familial Amyloid Polyneuropathy

3. Competitive Intelligence Analysis for Familial Amyloid Polyneuropathy

4. Familial Amyloid Polyneuropathy: Market Overview at a Glance

  • 4.1. Familial Amyloid Polyneuropathy Total Market Share (%) Distribution in 2017
  • 4.2. Familial Amyloid Polyneuropathy Total Market Share (%) Distribution in 2030

5. Familial Amyloid Polyneuropathy: Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Familial Amyloid Polyneuropathy Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Familial Amyloid Polyneuropathy Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Familial Amyloid Polyneuropathy Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Familial Amyloid Polyneuropathy Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Familial Amyloid Polyneuropathy Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Familial Amyloid Polyneuropathy Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Familial Amyloid Polyneuropathy Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Familial Amyloid Polyneuropathy Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Familial Amyloid Polyneuropathy Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Familial Amyloid Polyneuropathy Treatment and Management
  • 8.2. Familial Amyloid Polyneuropathy Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Familial Amyloid Polyneuropathy Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Familial Amyloid Polyneuropathy: Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Familial Amyloid Polyneuropathy Market Size in 7MM
  • 13.3. Familial Amyloid Polyneuropathy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Familial Amyloid Polyneuropathy Total Market Size in the United States
    • 15.1.2. Familial Amyloid Polyneuropathy Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Familial Amyloid Polyneuropathy Total Market Size in Germany
    • 15.3.2. Familial Amyloid Polyneuropathy Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Familial Amyloid Polyneuropathy Total Market Size in France
    • 15.4.2. Familial Amyloid Polyneuropathy Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Familial Amyloid Polyneuropathy Total Market Size in Italy
    • 15.5.2. Familial Amyloid Polyneuropathy Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Familial Amyloid Polyneuropathy Total Market Size in Spain
    • 15.6.2. Familial Amyloid Polyneuropathy Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Familial Amyloid Polyneuropathy Total Market Size in the United Kingdom
    • 15.7.2. Familial Amyloid Polyneuropathy Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Familial Amyloid Polyneuropathy Total Market Size in Japan
    • 15.8.3. Familial Amyloid Polyneuropathy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Familial Amyloid Polyneuropathy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Familial Amyloid Polyneuropathy Epidemiology (2017-2030)
  • Table 2 : 7MM Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Familial Amyloid Polyneuropathy Epidemiology in Germany (2017-2030)
  • Table 6 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Familial Amyloid Polyneuropathy Epidemiology in France (2017-2030)
  • Table 8 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Familial Amyloid Polyneuropathy Epidemiology in Italy (2017-2030)
  • Table 10 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Familial Amyloid Polyneuropathy Epidemiology in Spain (2017-2030)
  • Table 12 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Familial Amyloid Polyneuropathy Epidemiology in the UK (2017-2030)
  • Table 14 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Familial Amyloid Polyneuropathy Epidemiology in Japan (2017-2030)
  • Table 16 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Familial Amyloid Polyneuropathy Epidemiology (2017-2030)
  • Figure 2 : 7MM Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Familial Amyloid Polyneuropathy Epidemiology in the United States (2017-2030)
  • Figure 4 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Familial Amyloid Polyneuropathy Epidemiology in Germany (2017-2030)
  • Figure 6 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Familial Amyloid Polyneuropathy Epidemiology in France (2017-2030)
  • Figure 8 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Familial Amyloid Polyneuropathy Epidemiology in Italy (2017-2030)
  • Figure 10 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Familial Amyloid Polyneuropathy Epidemiology in Spain (2017-2030)
  • Figure 12 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Familial Amyloid Polyneuropathy Epidemiology in the UK (2017-2030)
  • Figure 14 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Familial Amyloid Polyneuropathy Epidemiology in Japan (2017-2030)
  • Figure 16 : Familial Amyloid Polyneuropathy Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)